Vemurafenib and cutaneous adverse events - report of five cases

Giselle de Barros Silva, Adriana Pessoa Mendes, Mariana Petaccia de Macedo, Clóvis Antônio Lopes Pinto, Ivana Lameiras Gibbons, João Pedreira Duprat Neto

Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat metastatic and unresectable melanoma. Clinical trials have shown increased overall survival and progression-free survival in patients treated with Vemurafenib. However, cutaneous adverse events are common during treatment. We report fi ve cases of metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its cutaneous adverse events. Dermatologists and oncologists need to be aware of possible skin changes caused by this medication, which is increasingly employed in melanoma treatment. Monitoring of patients during therapy is important for early treatment of adverse cutaneous cutaneous adverse events, improvement in quality of life and adherence to treatment.